Clinical Trials Sponsored by Suzhou Connect Biopharmaceuticals, Ltd.

Total 144 results

Suzhou Connect Biopharmaceuticals, Ltd.

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

Atopic Dermatitis

China
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects

Healthy Adult Subjects

China
Suzhou Connect Biopharmaceuticals, Ltd.

Terminated

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

United States, China, Poland, Spain, Ukraine
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study On Human Mass Balance And Biotransformation

Healthy Adult Subjects

China
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

Moderate to Severe Persistent Asthma

United States, China, Hungary, Korea, Republic of, Poland
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

Moderate-to-severe Atopic Dermatitis

China
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

Moderate to Severe Ulcerative Colitis

United States, China, Pakistan, Ukraine
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

United States, Australia, China, New Zealand
Suzhou Connect Biopharmaceuticals, Ltd.

Withdrawn

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

United States
Connect Biopharma Australia Pty Ltd

Completed

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

Autoimmune Diseases

Australia, United States
Connect Biopharma Australia Pty Ltd

Completed

Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults

Healthy Adult Subjects

Australia
Suzhou Connect Biopharmaceuticals, Ltd.
Tigermed Consulting Co., Ltd; Nucleus Network Ltd

Completed

Phase 1 Study Accessing the Safety and Tolerability of CBP-307

Autoimmune Diseases

Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

Ovarian Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants

Healthy Participants

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Moderate-to-Severe Plaque Psoriasis

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors

Advanced Malignant Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Ankylosing Spondylitis

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Breast Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) (COVID-19)

COVID-19 | Pneumonia

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis

Atopic Dermatitis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Safety and Tolerability Study of Jaktinib

Myelofibrosis

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (AA)

Alopecia Areata

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Cervical Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis

Lupus Nephritis
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Metastatic Colorectal Cancer (mCRC)

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Hydrochloride Cream For Atopic Dermatitis

Atopic Dermatitis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (AA)

Alopecia Areata

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis (PSO)

Moderate-to-Severe Plaque Psoriasis

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Gastric or Gastroesophageal Junction Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. (DTC)

Differentiated Thyroid Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer

Gastric Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis (AD)

Atopic Dermatitis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Donafenib for Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Advanced Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Advanced Malignant Tumors

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer (DTC)

Differentiated Thyroid Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects

NSCLC

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

The Mass Balance and Biotransformation of [14C]Donafenib in Healthy Adult Man

Healthy Male Adult

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Small Cell Lung Cancer | Neuroendocrine Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Solid Tumor

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG005 in Patients With Advanced Solid Tumors

Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors

Advanced Malignant Tumor

China

Clinical Trials Sponsored by Suzhou Connect Biopharmaceuticals, Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations